"Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.Cipla gets EIR from USFDA for Invagen manufacturing facility
"Following the inspection by the United States Food and Drug Administration (USFDA) at the lnvagen (US) manufacturing facility from December 2, 2019 to December 6, 2019, the company has received the establishment inspection report (EIR), indicating closure of the inspection," Cipla said in a filing to BSE.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
No comments:
Post a Comment